Patients
who begin therapy with a lipid-lowering drug in the hospital have
better long-term compliance
Patients who begin therapy with a cholesterol-lowering
drug in the hospital have better long-term compliance than patients
who initiate use at home, according to an article in the November
24th issue of the Archives of Internal Medicine.
Despite data demonstrating the health benefits
of these agents, they remain underused in actual practice, according
to information in the article. In the current work, American investigators
studied whether initiation as an inpatient rather than an outpatient
had any effect on long-term adherence to the drug regimen.
Researchers used data from 69 centers in the
United States and Canada that had participated in the Evaluation
in PTCA to Improve Long-term Outcome With Abciximab GP IIb/IIIa
Blockade (EPILOG) trial. The EPILOG trial enrolled patients hospitalized
for treatment for heart disease and randomized them to placebo or
lipid-lowering drugs. All patients were older than 21 years and
were not taking lipid-lowering drugs when hospitalized. Of the total
of 1,126 patients, 175 had started active drug therapy before leaving
the hospital and 1,951 were discharged without having started therapy.
At 6 months, 134 people (77 percent) who had
started drug therapy in the hospital were still taking the drug.
In contrast, 494 people (25 percent) whose doctor prescribed the
medication after discharge were still taking their medicine.
"We found that initiation of lipid-lowering
agents before discharge was the most important independent predictor
of their use at follow-up," the authors wrote. "In fact,
patients in whom lipid-lowering therapy was initiated before discharge
were nearly 3 times as likely to be taking these agents 6 months
later."
The researchers concluded, "Our
findings suggest that inpatient initiation of lipid-lowering therapy
for the secondary prevention of coronary disease is an effective
strategy to enhance subsequent use. Other modifiable factors that
influence the long-term use of these agents must be identified if
we are to bridge the gap between the current evidence base and practice
of preventive medicine."
|